Tomedes Supports a U.S. Pharmaceutical Company's Regulatory Meeting with Japanese PMDA Reviewers Through Remote Consecutive Interpretation

The Client

• Company name: Veridion Pharma (pseudonym)
• What does the company do? A U.S.-based mid-size pharmaceutical company specializing in oncology therapeutics, with an active pipeline of investigational drugs at various stages of clinical development and a strategic objective of securing regulatory approval in Japan as part of its Asia-Pacific market entry program.
• Deadline: Scheduled session with a fixed date, interpreter briefing and preparation required 5 business days in advance
• What do they need? Veridion required a certified consecutive interpreter for a 3-hour remote pre-submission meeting between its regulatory affairs team and reviewers from Japan's Pharmaceuticals and Medical Devices Agency (PMDA). The meeting covered the proposed development plan for an investigational oncology compound, including preclinical data summaries, proposed clinical trial design, patient population criteria, and regulatory pathway questions. All dialogue would be interpreted consecutively (English to Japanese and Japanese to English) with the interpreter managing real-time turn-taking between Veridion's U.S. regulatory team and the PMDA panel. The meeting would be conducted via a secure video conferencing platform, with PMDA reviewers participating from Tokyo and Veridion's team joining from its U.S. headquarters.

The Challenges

Interpreting a regulatory affairs meeting with a national health authority is not the same as interpreting a business negotiation or a clinical conference presentation. The stakes are institutional, PMDA reviewers are assessing whether a company's proposed development plan is scientifically sound and regulatorily viable. The interpreter is not a passive conduit; every rendered statement becomes part of the substantive record of the meeting. Veridion faced three challenges that required more than a standard medical interpretation workflow.

1. First, highly specialized oncology and regulatory science terminology requiring precise Japanese rendering

PMDA pre-submission meetings involve technical language that sits at the intersection of clinical pharmacology, oncology science, and Japanese pharmaceutical regulation. Terms covering pharmacokinetic and pharmacodynamic parameters, dose-escalation trial designs, patient selection criteria under Japanese clinical guidelines, and PMDA-specific regulatory pathway designations all have established Japanese equivalents within Japan's regulatory science framework — equivalents that differ from general medical Japanese and from the terminology used in FDA or EMA regulatory contexts. An interpreter without direct familiarity with PMDA regulatory language would be working from general medical vocabulary in a setting where the PMDA reviewers expect to hear the precise terms used in Japan's pharmaceutical review process. Imprecise rendering of a pharmacokinetic parameter, a patient eligibility criterion, or a regulatory pathway designation could cause a PMDA reviewer to misunderstand the scope of Veridion's proposed development plan.

2. Second, consecutive interpretation in a multi-party remote setting requiring precise turn management

A PMDA pre-submission meeting is not a monologue — it is an active dialogue between a company's regulatory team and a panel of scientific reviewers who ask detailed technical questions, seek clarifications, and probe the scientific rationale behind development decisions. In a consecutive interpretation setting, the interpreter must manage the pace of the dialogue, signal to speakers when to pause, retain complex technical statements in memory before rendering them, and do so across a video conferencing platform where the visual and audio cues that support turn-taking in in-person settings are reduced or absent. Latency, speaker overlap, and the absence of physical presence all require the interpreter to actively manage the flow of the session — a competency that goes beyond linguistic skill into meeting facilitation under technical constraints.

3. Lastly, the confidentiality requirements of a pre-submission regulatory meeting

PMDA pre-submission meetings involve unpublished clinical development data, proprietary compound information, and regulatory strategy details that are commercially sensitive and subject to strict confidentiality obligations. The interpreter would have access to investigational drug data, preclinical summaries, and proposed trial designs that had not yet entered the public domain. Veridion required an interpreter who had signed a pharmaceutical-grade NDA, had demonstrable experience handling confidential regulatory data, and operated within a secure remote interpretation framework — not a general-purpose video conferencing environment.

Why Tomedes?

Veridion selected Tomedes based on its experience with pharmaceutical and regulatory interpretation and its ability to source an interpreter with direct familiarity with PMDA regulatory affairs language. The pre-submission meeting context required a linguist who understood not just medical Japanese but the specific vocabulary and register of Japan's pharmaceutical regulatory review process, a specialization that Tomedes was able to identify within its network of subject-matter expert interpreters with life sciences backgrounds.

A dedicated project manager with experience coordinating pharmaceutical interpretation engagements was assigned to the project, and structured the preparation workflow to include a pre-session briefing and terminology review before the meeting date.

The Solution

1. First, a pre-session terminology briefing and preparation package

Five business days before the meeting, Tomedes worked with Veridion's regulatory affairs lead to prepare the assigned interpreter with a structured briefing package — covering the investigational compound's therapeutic area, the key pharmacokinetic and pharmacodynamic parameters under discussion, the proposed clinical trial design, and the specific PMDA regulatory pathway questions Veridion intended to raise. The package included a bilingual glossary of 41 terms covering oncology clinical terminology, PMDA-specific regulatory designations, and the Japanese equivalents of the key scientific parameters to be discussed. The interpreter reviewed the package, flagged two terms where PMDA regulatory usage differed from general pharmaceutical Japanese, and confirmed the approved Japanese-language equivalents with Veridion's Japan regulatory counsel before the session. The interpreter also reviewed PMDA's publicly available guidance documents on the relevant drug development pathway to ensure familiarity with the agency's current review framework.

2. Second, a certified pharmaceutical interpreter with PMDA regulatory experience

The interpretation was handled by a certified Japanese-English medical interpreter with documented experience in pharmaceutical regulatory affairs interpretation, including prior engagements supporting company-PMDA dialogue at pre-submission and consultation meetings. The interpreter managed the consecutive turn-taking protocol across the 3-hour remote session — signaling speakers when to pause, rendering each statement completely before the next speaker continued, and maintaining the technical register expected in a formal regulatory dialogue. Where a PMDA reviewer's question involved a compound term or regulatory concept that required a brief clarification of the Japanese rendering, the interpreter provided the clarification transparently and immediately, maintaining the integrity of the dialogue without interrupting its flow. All session content was handled under a pharmaceutical-grade NDA executed prior to the engagement.

3. Lastly, secure remote interpretation infrastructure and post-session support

The session was conducted over a secure, end-to-end encrypted video platform configured to HIPAA-equivalent standards for pharmaceutical data handling. Tomedes provided technical support before the session to verify audio quality, latency, and turn-taking protocols with both the Veridion team and the PMDA-side connection. Following the session, Tomedes provided Veridion's regulatory affairs team with the finalized bilingual glossary as a reusable reference asset for future PMDA engagements — including any follow-up written correspondence arising from the pre-submission meeting that would require Japanese translation.

Conclusion

Regulatory meetings with national health authorities are not recoverable if misunderstanding occurs in the session. When Veridion's regulatory affairs team concluded their pre-submission meeting with PMDA reviewers, every technical exchange (from pharmacokinetic parameter discussions to patient eligibility criteria questions) had been interpreted with the precision and regulatory register that a PMDA dialogue requires. Veridion's regulatory affairs lead confirmed that the PMDA panel's questions and responses had been fully and accurately rendered throughout the session, and that the meeting produced the substantive guidance on clinical trial design that Veridion needed to proceed with its Japan development plan.

Are you preparing for a regulatory affairs meeting, clinical development discussion, or pharmaceutical conference requiring English to Japanese interpretation or any other language combination? Contact Tomedes today for a free consultation.

Key Details